RSS   Newsletter   Contact   Advertise with us
Post Online Media

Deciphera expands board with appointment of two new directors

Share on Twitter Share on LinkedIn
Staff Writer | Waltham, Ma., USA | Friday October 7, 2016 6:21AM ET
DecipheraOctober 7, 2016, Waltham, Ma., USA - Deciphera Pharmaceuticals, a clinical-stage biotechnology company, announced that it has elected Edward J. Benz, Jr. and Patricia L. Allen to its board of directors.
Please disable your ad blocker for POST to be able to enjoy our free content.
Dr. Benz is the outgoing President and Chief Executive Officer of the Dana-Farber Cancer Institute, which he led from 2000-2016. Dr. Benz is also the Richard and Susan Smith Distinguished Professor of Medicine and Professor of Pediatrics and Genetics at Harvard Medical School.

Immediately prior to assuming the presidency at Dana-Farber, Dr. Benz was chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine.

He received a bachelor’s degree, cum laude, from Princeton University, a medical degree, magna cum laude, from Harvard Medical School, and a master’s degree (privatum) from Yale University.

Author of more than 300 articles, books, chapters, reviews, and abstracts, Dr. Benz is a past president of both the American Society of Hematology and the American Society of Clinical Investigation, and was an associate editor of the New England Journal of Medicine from 2002-2016.

Ms. Allen is the Chief Financial Officer of Zafgen, Inc. Ms. Allen has served as Chief Financial Officer of Zafgen, Inc. since January 2013.

Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly-traded and private companies.

From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim CFO services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development.

Previously, from 2004 to 2011, she served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly-traded biotechnology company.

Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly-traded biotechnology company, for twelve years most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP.

She graduated summa cum laude from Bryant College with a B.S. in business administration.


 LATEST MOVES FROM Massachusetts 

POST Online Media Contact

 More inside POST